Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revision Previous revision
Next revision
Previous revision
ad [2017/02/25 16:57]
sflitman [Alzheimer's Disease and Mild Cognitive Impairment]
ad [2018/11/18 10:50]
sflitman [Alzheimer's Disease and Mild Cognitive Impairment]
Line 4: Line 4:
  
 ^ Condition(s) ^ Type of Drug ^ Phase ^ Add-On ^ Placebo ^ Duration ^ Open Label Extension ^ ^ Condition(s) ^ Type of Drug ^ Phase ^ Add-On ^ Placebo ^ Duration ^ Open Label Extension ^
-Mild Cognitive Impairment ​and Mild AD | Intravenous anti-amyloid ​antibody ​ |  ​II  ​| ​ Yes  |  ​25%  |  18 months ​ |  ​1+ years  | +MCI and Mild AD | Intravenous anti-tau antibody ​ |  ​III  ​| ​ Yes  |  ​33%  |  18 months ​ |  ​years  | 
-Mild Cognitive Impairment ​and Mild AD | Intravenous anti-amyloid antibody  ​|  III  |  Yes  |  ​33%  |  ​18 months ​ ​|  ​years  | +MCI and Mild AD | Oral BACE inhibitor ​|  III  |  Yes  |  ​50%  |  ​48 weeks  ​|  ​1+ years  | 
-Early AD | Oral inhaled Cromolyn + Ibuprofen ​|  III  |  Yes  |  ​25%  |  ​72 ​weeks   ​|  ​None  | +MCI and Mild AD | Counterpulsation device ​|  III  |  Yes  |  ​50%  | 24 weeks  |  ​1 year  | 
-Mild AD | Oral RAGE antagonist |  III  |  Yes  |  50%  |  ​18 months ​ ​|  ​1+ years  | +Agitation in AD | Oral 5HT2A antagonist |  III  |  Yes  |  50%  |  ​8 weeks  ​|  ​None  | 
-Mild AD | Oral BACE inhibitor ​|  III  |  Yes  |  ​50%  |  ​48 weeks  |  ​1+ years  | +Agitation in AD | Oral combination of two approved drugs |  III  |  Yes  |  ​33%  |  ​weeks  |  ​None  ​| ​
  
 Also see [[imaging|Imaging]]. Also see [[imaging|Imaging]].
Print/export
QR Code
QR Code ad (generated for current page)